CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 22, 2019
Result type: Reports
Project Number: SR0518-000
Product Line: Reimbursement Review

Generic Name: cyclosporine

Brand Name: Ikervis

Manufacturer: Santen Canada Incorporated

Therapeutic Area: keratitis, severe

Indications: keratitis, severe

Submission Type: Initial

Project Status: Withdrawn

Biosimilar: No

Fee Schedule: Schedule A

Key Milestones2

Call for patient input postedApril 17, 2017
Patient group input closedJune 06, 2017

- Patient input submission received

Patient input summary sent for review to patient input groupsJune 26, 2017
Patient group comments on input summary closedJuly 04, 2017

- Patient input summary feedback received

Submission receivedMay 15, 2017
Submission accepted for reviewMay 30, 2017
Review initiatedMay 31, 2017

- Voluntarily withdrawn by the manufacturer on 2017-July-11